SequelSEC

ALX ONCOLOGY HOLDINGS INC ALXO

Pharmaceutical Preparations · CIK 0001810182 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2022-12-31
Operating income
Unavailable
Fiscal year ended 2022-12-31
Free cash flow
Unavailable
Fiscal year ended 2022-12-31

This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ALX ONCOLOGY HOLDINGS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ALX ONCOLOGY HOLDINGS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
RevenueUnavailableUnavailable$0$0$527.00K$655.00K$1.21M$1.26M$1.30MUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailable-$17.82M-$9.81M-$10.79M-$5.24M-$7.73M-$3.03M-$4.19MUnavailable
Net incomeUnavailableUnavailable-$18.77M-$10.18M-$11.33M-$5.45M-$7.76M-$3.04M-$4.20MUnavailable
Research & developmentUnavailableUnavailable$12.14M$5.33M$7.66M$3.83M$6.74M$2.21M$3.63MUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailable-$18.59M-$10.15M-$11.31M-$5.45M-$7.76M-$3.04M-$4.19MUnavailable
Income tax expenseUnavailableUnavailable$182.00K$35.00K$20.00K$4.00K$9.00K$8.00K$8.00KUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailable$5.68M$4.48M$3.17M$1.47M$1.11M$938.00K$679.00KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ALX ONCOLOGY HOLDINGS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Cash & equivalents$48.82M$363.67M$434.22M$259.48M$98.10MUnavailable$9.02MUnavailableUnavailableUnavailable
Total assets$306.49M$380.18M$436.05M$262.45M$103.11MUnavailable$10.68MUnavailableUnavailableUnavailable
Current assets$270.97M$367.02M$435.99M$262.40M$100.66MUnavailable$9.81MUnavailableUnavailableUnavailable
Total liabilities$43.02M$17.13M$6.21M$10.43M$12.47MUnavailable$10.95MUnavailableUnavailableUnavailable
Current liabilities$28.32M$15.30M$6.20M$7.20M$7.72MUnavailable$4.98MUnavailableUnavailableUnavailable
Total equity incl. NCI$263.46M$363.05M$429.84M$252.02M-$84.40M-$75.93M-$70.64M-$62.98M-$60.04M-$51.78M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$175.04MUnavailable$70.36MUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$9.39MUnavailableUnavailable$3.19M$3.93MUnavailable$5.42MUnavailableUnavailableUnavailable
Accounts payable$8.07M$3.76M$4.00K$1.42M$1.86MUnavailable$3.75MUnavailableUnavailableUnavailable

Cash flow

ALX ONCOLOGY HOLDINGS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Operating cash flowUnavailableUnavailable-$13.62M-$9.55M-$6.16M-$8.96M-$2.87M-$3.19MUnavailableUnavailable
Capital expendituresUnavailableUnavailable$11.00K$10.00K$0$10.00K-$62.00K$0UnavailableUnavailable
Investing cash flowUnavailableUnavailable-$11.00K$631.00K$0-$10.00K$62.00K$0UnavailableUnavailable
Financing cash flowUnavailableUnavailable$188.36M$170.30M-$769.00K$104.99M$5.93M$0UnavailableUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailable$1.74M$689.00K$2.85M$151.00K$75.00K$86.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$0$100.00K$100.00K$113.00K$100.00K$100.00K$100.00KUnavailable

Derived

ALX ONCOLOGY HOLDINGS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-12-312021-12-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Free cash flowUnavailableUnavailable-$13.63M-$9.56M-$6.16M-$8.97MUnavailable-$3.19MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable-2046.9%-800.3%-637.5%-241.6%-323.5%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-1169.4%-1369.9%Unavailable-253.7%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable541.4%23.1%6.2%6.8%UnavailableUnavailable
Current ratio9.57x24.00x70.28x36.46x13.04xUnavailable1.97xUnavailableUnavailableUnavailable
Revenue YoY growthUnavailableUnavailable-100.0%-100.0%-59.3%UnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable-2150.1%Unavailable-640.1%-242.4%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable1454.1%584.4%555.2%176.0%280.2%Unavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable0.0%1.5%-5.1%0.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALXO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.